AR111840A1 - Polipéptidos que antagonizan la señalización wnt en células tumorales - Google Patents
Polipéptidos que antagonizan la señalización wnt en células tumoralesInfo
- Publication number
- AR111840A1 AR111840A1 ARP180101427A ARP180101427A AR111840A1 AR 111840 A1 AR111840 A1 AR 111840A1 AR P180101427 A ARP180101427 A AR P180101427A AR P180101427 A ARP180101427 A AR P180101427A AR 111840 A1 AR111840 A1 AR 111840A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptides
- wnt signaling
- tumor cells
- methods
- antagonize wnt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17173782 | 2017-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111840A1 true AR111840A1 (es) | 2019-08-21 |
Family
ID=59021278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101427A AR111840A1 (es) | 2017-05-31 | 2018-05-30 | Polipéptidos que antagonizan la señalización wnt en células tumorales |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11033636B2 (enExample) |
| EP (1) | EP3630816B1 (enExample) |
| JP (1) | JP7216024B2 (enExample) |
| KR (1) | KR102717656B1 (enExample) |
| CN (1) | CN110637030B (enExample) |
| AR (1) | AR111840A1 (enExample) |
| AU (1) | AU2018276409B2 (enExample) |
| BR (1) | BR112019022729A2 (enExample) |
| CA (1) | CA3060401A1 (enExample) |
| CL (1) | CL2019003419A1 (enExample) |
| CO (1) | CO2019012329A2 (enExample) |
| EA (1) | EA201992808A1 (enExample) |
| ES (1) | ES2979194T3 (enExample) |
| HU (1) | HUE067691T2 (enExample) |
| IL (1) | IL270854B2 (enExample) |
| MA (1) | MA48760A (enExample) |
| MX (1) | MX2019014331A (enExample) |
| MY (1) | MY200744A (enExample) |
| PE (1) | PE20200610A1 (enExample) |
| PH (1) | PH12019502602A1 (enExample) |
| PL (1) | PL3630816T3 (enExample) |
| TW (1) | TWI887192B (enExample) |
| UA (1) | UA125761C2 (enExample) |
| WO (1) | WO2018220080A1 (enExample) |
| ZA (1) | ZA201906610B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA48760A (fr) * | 2017-05-31 | 2020-04-08 | Boehringer Ingelheim Int | Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales |
| JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
| AU2018393073B2 (en) | 2017-12-19 | 2025-09-18 | Surrozen Operating, Inc. | Wnt surrogate molecules and uses thereof |
| CA3085785A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-lrp5/6 antibodies and methods of use |
| CN117946267A (zh) | 2017-12-19 | 2024-04-30 | 瑟罗泽恩奥普瑞汀公司 | 抗卷曲蛋白抗体和使用方法 |
| WO2020080941A1 (en) * | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
| EP3924381A4 (en) * | 2019-02-11 | 2023-07-26 | Surrozen Operating, Inc. | MODULATION OF WNT SIGNALING IN EYE DISEASES |
| CN113646048A (zh) * | 2019-03-29 | 2021-11-12 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
| CA3147827A1 (en) * | 2019-08-14 | 2021-02-18 | Modmab Therapeutics Inc. | Antibodies that bind to lrp5 proteins and methods of use |
| WO2023250402A2 (en) * | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| KR20230011226A (ko) * | 2021-07-13 | 2023-01-20 | 인제대학교 산학협력단 | NEURL 유전자, 이를 포함하는 발현벡터 또는 NEURL 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물 |
| CN117897408A (zh) * | 2021-08-10 | 2024-04-16 | 热生物制品有限公司 | 新型tim-4结合剂的生成和表征 |
| CN114702588B (zh) * | 2022-04-27 | 2022-11-22 | 博际生物医药科技(杭州)有限公司 | 抗Nectin-4抗体和双特异性抗体 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE452975T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ES2285767T3 (es) | 1997-04-15 | 2007-11-16 | MERCK & CO., INC. | Receptor de ldl. |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1395285A4 (en) | 2001-05-17 | 2005-06-01 | Genome Therapeutics Corp | REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS |
| DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2135879A3 (en) * | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| EP1558646A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses thereof |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| BRPI0518151A2 (pt) | 2004-10-13 | 2009-06-16 | Ablynx Nv | polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| WO2007027509A2 (en) | 2005-08-31 | 2007-03-08 | Biogen Idec Ma Inc. | Evaluating and treating scleroderma |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| CA2663042A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| EP2097449A1 (en) | 2006-12-05 | 2009-09-09 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| AU2009221106A1 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| JP2011516603A (ja) | 2008-04-17 | 2011-05-26 | アブリンクス エン．ヴェー． | 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド |
| US8716243B2 (en) | 2008-05-28 | 2014-05-06 | St. Jude Childen's Research Hospital | Methods of effecting Wnt signaling through Dkk structural analysis |
| EP4219545A1 (en) | 2009-12-23 | 2023-08-02 | Novartis AG | Method for decreasing immunogenicity |
| CA2788993A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| EA201201227A1 (ru) | 2010-03-03 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Бипаратопные а-бета-связывающие полипептиды |
| EP2550295A1 (en) * | 2010-03-24 | 2013-01-30 | F. Hoffmann-La Roche AG | Anti-lrp6 antibodies |
| CA2798390A1 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| EP2566892B1 (en) * | 2010-05-06 | 2017-12-20 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
| AU2012211277A1 (en) * | 2011-01-28 | 2013-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | Wnt compositions and methods of use thereof |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US8790650B2 (en) | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
| JP6258199B2 (ja) | 2011-06-23 | 2018-01-10 | アブリンクス エン．ヴェー． | 免疫グロブリン単一可変ドメインを伴うアッセイにおける非特異的タンパク質干渉を予測、検出及び低減するための技術 |
| UA118833C2 (uk) | 2011-08-17 | 2019-03-25 | Ґлаксо Ґруп Лімітед | Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1 |
| EP3290442A1 (en) | 2011-11-04 | 2018-03-07 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs |
| SG10201601747XA (en) * | 2012-01-18 | 2016-04-28 | Genentech Inc | Anti-LRP5 Antibodies And Methods Of Use |
| WO2017085172A2 (en) * | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
| UA122079C2 (uk) * | 2015-12-04 | 2020-09-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Поліпептид, що специфічно зв'язується з lrp5 і lrp6 |
| MA48760A (fr) * | 2017-05-31 | 2020-04-08 | Boehringer Ingelheim Int | Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales |
| CN113646048A (zh) * | 2019-03-29 | 2021-11-12 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
-
2018
- 2018-05-30 MA MA048760A patent/MA48760A/fr unknown
- 2018-05-30 TW TW107118382A patent/TWI887192B/zh active
- 2018-05-30 EP EP18729376.6A patent/EP3630816B1/en active Active
- 2018-05-30 EA EA201992808A patent/EA201992808A1/ru unknown
- 2018-05-30 CA CA3060401A patent/CA3060401A1/en active Pending
- 2018-05-30 HU HUE18729376A patent/HUE067691T2/hu unknown
- 2018-05-30 US US15/992,345 patent/US11033636B2/en active Active
- 2018-05-30 CN CN201880033136.9A patent/CN110637030B/zh active Active
- 2018-05-30 JP JP2019565865A patent/JP7216024B2/ja active Active
- 2018-05-30 AU AU2018276409A patent/AU2018276409B2/en active Active
- 2018-05-30 UA UAA201911920A patent/UA125761C2/uk unknown
- 2018-05-30 PL PL18729376.6T patent/PL3630816T3/pl unknown
- 2018-05-30 MY MYPI2019006657A patent/MY200744A/en unknown
- 2018-05-30 AR ARP180101427A patent/AR111840A1/es unknown
- 2018-05-30 KR KR1020197033590A patent/KR102717656B1/ko active Active
- 2018-05-30 MX MX2019014331A patent/MX2019014331A/es unknown
- 2018-05-30 WO PCT/EP2018/064295 patent/WO2018220080A1/en not_active Ceased
- 2018-05-30 PE PE2019002493A patent/PE20200610A1/es unknown
- 2018-05-30 BR BR112019022729A patent/BR112019022729A2/pt unknown
- 2018-05-30 ES ES18729376T patent/ES2979194T3/es active Active
-
2019
- 2019-10-08 ZA ZA2019/06610A patent/ZA201906610B/en unknown
- 2019-10-31 CO CONC2019/0012329A patent/CO2019012329A2/es unknown
- 2019-11-20 PH PH12019502602A patent/PH12019502602A1/en unknown
- 2019-11-24 IL IL270854A patent/IL270854B2/en unknown
- 2019-11-25 CL CL2019003419A patent/CL2019003419A1/es unknown
-
2021
- 2021-05-10 US US17/316,042 patent/US12285493B2/en active Active
-
2025
- 2025-03-20 US US19/085,495 patent/US20250345448A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111840A1 (es) | Polipéptidos que antagonizan la señalización wnt en células tumorales | |
| CO2018005680A2 (es) | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales | |
| MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
| CY1123290T1 (el) | Ενωσεις και μεθοδοι χρησης | |
| AR113862A1 (es) | Anticuerpos anti-cd47 y sus usos para tratar cáncer | |
| CY1122227T1 (el) | Ρυθμιση δραστικοτητας συμπληρωματος | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| ECSP17062716A (es) | Heterociclos bicíclicos como inhibidores de fgfr4 | |
| MX2018010484A (es) | Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer. | |
| MX381046B (es) | Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. | |
| MX373323B (es) | Procesos de siembra en serie y usos de los mismos. | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| MX2017006283A (es) | Peptidos macrociclicos utiles como inmunomoduladores. | |
| CO2017004314A2 (es) | Compuestos anti-tnf | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| MX2018000778A (es) | Metodos para tratar trastornos mediados por hepcidinas. | |
| MX2017006167A (es) | Compuestos que interactúan con glicanos y métodos de uso. | |
| CL2018002810A1 (es) | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada. | |
| MX385138B (es) | Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes. | |
| MX373818B (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| UY37980A (es) | Compuestos novedosos para tratar enfermedades parasitarias | |
| EA201691887A1 (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| UY36286A (es) | Tratamientos médicos basados en anamorelina | |
| MX2016015163A (es) | Biomarcadores mit y metodos para su uso. |